Paper5289712
Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.
Ho DH and 1 other. Clin Pharmacol Ther, 1971. Cited by 377 papers, by iCite.
Cite this record
ConductScience Library. Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Papers, record 5289712. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/5289712
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Cytarabine | Major topic |
| Administration, Oral | |
| Animals | |
| Arabinose | |
| Erythrocytes | |
| Half-Life | |
| Humans | |
| Infusions, Parenteral | |
| Injections, Intravenous | |
| Injections, Spinal | |
| Leukemia L1210 | |
| Leukemia, Myeloid | |
| Mice | |
| Neoplasm Transplantation | |
| Nucleosides | |
| Time Factors | |
| Tritium | |
| Uracil |
Source PubMed
Cited by76
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 377 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37670479 | Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs. | J Vet Intern Med | 2023 | https://conductscience.org/library/papers/37670479 | PubMed |
| 37363044 | Theoretical aspects of interaction of the anticancer drug cytarabine with human serum albumin. | Struct Chem | 2023 | https://conductscience.org/library/papers/37363044 | PubMed |
| 33328603 | Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia. | Leukemia | 2021 | https://conductscience.org/library/papers/33328603 | PubMed |
| 31200562 | Improving the Brain Delivery of Chemotherapeutic Drugs in Childhood Brain Tumors. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31200562 | PubMed |
| 31098682 | A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. | Cancer Chemother Pharmacol | 2019 | https://conductscience.org/library/papers/31098682 | PubMed |
| 30836199 | Film interface for drug testing for delivery to cells in culture and in the brain. | Acta Biomater | 2019 | https://conductscience.org/library/papers/30836199 | PubMed |
| 30041457 | Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/30041457 | PubMed |
| 26563190 | High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma. | J Neurooncol | 2016 | https://conductscience.org/library/papers/26563190 | PubMed |
| 25713072 | A metal-containing nucleoside that possesses both therapeutic and diagnostic activity against cancer. | J Biol Chem | 2015 | https://conductscience.org/library/papers/25713072 | PubMed |
| 24045660 | Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. | Br J Cancer | 2013 | https://conductscience.org/library/papers/24045660 | PubMed |
| 23666364 | High-dose cytarabine (HD araC) in the treatment of leukemias: a review. | Curr Hematol Malig Rep | 2013 | https://conductscience.org/library/papers/23666364 | PubMed |
| 20842542 | Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles. | AAPS PharmSciTech | 2010 | https://conductscience.org/library/papers/20842542 | PubMed |
| 20607357 | High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma. | J Neurooncol | 2011 | https://conductscience.org/library/papers/20607357 | PubMed |
| 19941076 | PCR-based methods for CDA K27Q and A70T genotyping: genotypes and alleles distribution in a central Italy population. | Mol Biol Rep | 2010 | https://conductscience.org/library/papers/19941076 | PubMed |
| 18836794 | AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity. | Int J Hematol | 2008 | https://conductscience.org/library/papers/18836794 | PubMed |
| 16446974 | Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. | Hum Genet | 2006 | https://conductscience.org/library/papers/16446974 | PubMed |
| 15825312 | Assessment of cytosine arabinoside as an antiviral agent in humans. | Antimicrob Agents Chemother | 1974 | https://conductscience.org/library/papers/15825312 | PubMed |
| 11572766 | Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia. | Jpn J Cancer Res | 2001 | https://conductscience.org/library/papers/11572766 | PubMed |
| 11417472 | Nucleoside analogues: mechanisms of drug resistance and reversal strategies. | Leukemia | 2001 | https://conductscience.org/library/papers/11417472 | PubMed |
| 11376564 | Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses. | Jpn J Cancer Res | 2001 | https://conductscience.org/library/papers/11376564 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/5289712
GET https://conductscience.org/api/papers/v1/5289712/cited_by?page=2